MustGrow Biologics Valuation

Is MGRO.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of MGRO.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate MGRO.F's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate MGRO.F's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for MGRO.F?

Key metric: As MGRO.F is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for MGRO.F. This is calculated by dividing MGRO.F's market cap by their current revenue.
What is MGRO.F's PS Ratio?
PS Ratio	19.8x
Sales	CA$4.71m
Market Cap	CA$95.02m

MGRO.F key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	19.3x
Enterprise Value/EBITDA	n/a
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does MGRO.F's PS Ratio compare to its peers?

The above table shows the PS ratio for MGRO.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	2.4x
KNGW Kenongwo Group US	4.2x	n/a	US$32.6m
MULG Muliang Viagoo Technology	4.1x	n/a	US$49.1m
AVD American Vanguard	0.3x	4.8%	US$176.5m
BIOX Bioceres Crop Solutions	0.9x	9.6%	US$404.7m
MGRO.F MustGrow Biologics	19.8x	n/a	US$95.0m

Price-To-Sales vs Peers: MGRO.F is expensive based on its Price-To-Sales Ratio (19.8x) compared to the peer average (1.8x).

Price to Sales Ratio vs Industry

How does MGRO.F's PS Ratio compare vs other companies in the US Chemicals Industry?

10 Companies	Price / Sales	Estimated Growth	Market Cap
TSE Trinseo	0.04x	5.0%	US$122.49m
ALTO Alto Ingredients	0.1x	3.1%	US$108.84m
BON Bon Natural Life	0.2x	n/a	US$6.27m
ABLT American Biltrite	0.02x	n/a	US$2.91m

10 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: MGRO.F is expensive based on its Price-To-Sales Ratio (19.8x) compared to the US Chemicals industry average (1.4x).

Price to Sales Ratio vs Fair Ratio

What is MGRO.F's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MGRO.F PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	19.8x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate MGRO.F's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Allied Gold

CA$1.1b

Explores for and produces mineral deposits in Africa.

AAUC.F

CA$2.47

16.0%

-18.0%

Ecora Resources

UK£162.5m

Operates as a natural resource royalty and streaming company in Australia, North and South America, Europe, and internationally.

ECRA.F

UK£0.82

-4.5%

-28.7%

Chemtrade Logistics Income Fund

CA$1.4b

Offers industrial chemicals and services in Canada, the United States, and South America.

CGIF.F

CA$8.20

0.8%

26.3%